Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy

被引：0

作者：

Witteles, R. ^{[1
]}

Sultan, M. B. ^{[2
]}

Gundapaneni, B. ^{[3
]}

Garcia-Pavia, P. ^{[4
,5
]}

机构：

[1] Stanford Univ, Sch Med, Stanford, CA USA

[2] Pfizer Inc, New York, NY USA

[3] Pfizer Inc, Groton, CT USA

[4] Hosp Univ Puerta Hierro Majadahonda, CIBERCV, Madrid, Spain

[5] Univ Francisco Vitoria, Madrid, Spain

来源：

EUROPEAN HEART JOURNAL | 2022年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：861 / 861

页数：1

共 50 条

[1] Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy
Witteles, Ronald
Jefferies, John L.
Kapa, Suraj
Cappelli, Francesco
Sultan, Marla B.
Gundapaneni, Balarama
Davis, Margot K.
Garcia-Pavia, Pablo
JACC: CARDIOONCOLOGY, 2024, 6 (04): : 592 - 598
[2] Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
Judge, Daniel P.
Alexander, Kevin M.
Cappelli, Francesco
Fontana, Marianna
Garcia-Pavia, Pablo
Gibbs, Simon D. J.
Grogan, Martha
Hanna, Mazen
Masri, Ahmad
Maurer, Mathew S.
Obici, Laura
Soman, Prem
Cao, Xiaofan
Lystig, Ted
Tamby, Jean-Francois
Siddhanti, Suresh
Castano, Adam
Katz, Leonid
Fox, Jonathan C.
Mahaffey, Kenneth W.
Gillmore, Julian D.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (10) : 1003 - 1014
[3] Atrial fibrillation is an independent predictor for all-cause mortality in ischaemic cardiomyopathy but not in dilated cardiomyopathy
Kleemann, T
Kilkowski, A
Lorenz, H
Jost, A
Kilkowski, C
Siegler, K
Senges, J
Rauch, B
EUROPEAN HEART JOURNAL, 2004, 25 : 242 - 242
[4] Atrial fibrillation is an independent predictor for all-cause mortality in ischemic cardiomyopathy but not in dilated cardiomyopathy
Kleemann, T
Kilkowski, A
Lorenz, H
Jost, A
Seidl, KH
Siegler, K
Rauch, B
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 97A - 98A
[5] Targeted Screening for Transthyretin Amyloid Cardiomyopathy in Patients With Atrial Fibrillation
Prasad, Pooja
Howell, Stacey
Sanghai, Saket
Stecker, Eric
Henrikson, Charles A.
Masri, Ahmad
Nazer, Babak
CIRCULATION, 2022, 146 (22) : 1730 - 1732
[6] The impact of education level on all-cause mortality in patients with atrial fibrillation
Sztaniszlav, Aron
Bjorkenheim, Anna
Magnuson, Anders
Bryngelsson, Ing-Liss
Edvardsson, Nils
Poci, Dritan
SCIENTIFIC REPORTS, 2024, 14 (01):
[7] Growth differentiation factor-15 predicts all-cause mortality in patients with atrial fibrillation
Nopp, Stephan
Koenigsbruegge, Oliver
Kraemmer, Daniel
Pabinger, Ingrid
Ay, Cihan
WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : 82 - 82
[8] Patterns of Anticoagulation Use and All-Cause of Mortality in Cancer Patients with Atrial Fibrillation
Han, Xu
Yang, Xiaolei
Hidru, Tesfaldet H.
Wang, Chengfang
Xia, Yunlong
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (02) : 244 - 253
[9] Tafamidis and Incidence of Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy
Girvin, Zachary P.
Sweat, Austin O.
Kochav, Stephanie M.
Maurer, Mathew S.
Dizon, Jose
Wan, Elaine Y.
Biviano, Angelo
Garan, Hasan
Yarmohammadi, Hirad
JACC-CLINICAL ELECTROPHYSIOLOGY, 2023, 9 (04) : 586 - 587
[10] EVOLUTION OF ATRIAL FIBRILLATION PATTERNS AND IMPACT ON ALL-CAUSE MORTALITY IN A CONTEMPORARY COHORT OF EUROPEAN PATIENTS WITH ATRIAL FIBRILLATION
Vitolo, Marco
Bonini, Niccolo
Imberti, Jacopo Francesco
Mei, Davide
Forzati, Nicola
Laus, Vera
Stuani, Marco
Chiriaco, Francesco
Menozzi, Matteo
Francesco Romiti, Giulio
Proietti, Marco
Malavasi, Vincenzo Livio
Lip, Gregory Yh
Boriani, Giuseppe
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24

← 1 2 3 4 5 →